ErbB-2 is an orphan receptor that belongs to a family of tyrosine kinase receptors for either epidermal growth factor (EGF) or Neu dierentiation factor (NDF/ neuregulin). Because overexpression of the erbB-2 proto-oncogene is frequently associated with an aggressive clinical course of certain human adenocarcinomas, the encoded protein is an attractive target for immunotherapy. Indeed, certain monoclonal antibodies (mAbs) to ErbB-2 eectively inhibit tumor growth in animal models and in clinical trials, but the underlying mechanism is incompletely understood. To study this question, we generated a large battery of mAbs to ErbB-2, that were classi®ed epitopically. Whereas most antibodies stimulated tyrosine phosphorylation of ErbB-2, their anti-tumor eect correlated with its accelerated endocytic degradation. One group of tumor-inhibitory mAbs (Class II mAbs) was elicited by the most antigenic site of ErbB-2, and inhibited in trans binding of NDF and EGF to their direct receptors. The inhibitory eect was due to acceleration of ligand dissociation, and it resulted in the reduction of the ability of ErbB-2 to transactivate the mitogenic signals of NDF and EGF. These results identify two potential mechanisms of antibody-induced therapy: acceleration of ErbB-2 endocytosis by homodimerization and blocking of heterodimerization between ErbB-2 and growth factor receptors.
Introduction
The identi®cation of tumor associated antigens (TAA) accessible on human cancer cells, hailed immunotherapeutic approaches relying on speci®c recognition of neoplasms (Hellstrom and Hellstrom, 1989) . Extensive eorts have indeed been invested in examining the plausibility of anti-TAA monoclonal antibodies (mAbs) in the treatment of human malignancies proving promising in laboratory and clinic (Goldenberg, 1993) . Protooncogene-encoded growth factor receptors are putative targets for such recognitiondependent therapy, due to their suggested role in pathological proliferation of cells (Aaronson, 1991) . ErbB-2, a receptor-like tyrosine kinase, has been repeatedly implicated in cell transformation (Hynes and Stern, 1994; Stancovski et al., 1994) . Ampli®cation of the corresponding gene and overexpression of the protein itself were observed in 20% to 30% of adenocarcinomas of the breast (King et al., 1985; Slamon et al., 1987 Slamon et al., , 1989 , ovary (Slamon et al., 1989) , lung (Kern et al., 1990) and stomach (Park et al., 1989) . Causative relationships between the cellular ErbB-2 content and the tumor's proliferative capacity and aggressiveness have been supported by dierent lines of evidence. When overexpressed in mouse ®broblasts, the human gene conferred a transformed phenotype in vitro and tumorigenesis in vivo (Di Fiore et al., 1987; Hudziak et al., 1987) . Consistently, receptor overexpression is considered a predictor of poor survival and short time to relapse (Slamon et al., 1987 (Slamon et al., , 1989 . Direct interference with the transforming potential of ErbB-2 has thus become a subject of great interest. Antibodies directed against the extracellular domain of either a mutated version of the rodent homolog of this receptor-like molecule, or against the human wild-type protein have been shown to confer inhibitory, as well as stimulatory, eects on tumor growth in vivo (Drebin et al, 1986; Fendly et al., 1990; Hudziak et al., 1989; Stancovski et al., 1991) . Moreover, a murine antibody capable of such growth inhibition has been recently humanized and tested in a phase II clinical trial, resulting in anti-tumor activity in patients with ErbB-2-overexpressing metastatic breast cancers (Baselga et al., 1996) .
Although the potential therapeutic use of anti-ErbB-2 mAbs is presently acknowledged and intensely examined, the molecular mechanisms underlying these eects are not well understood. Accelerated down-regulation of the receptor has been suggested to mediate antibody inhibition of cell transformation (Hudziak et al., 1989; van Leeuwen et al., 1990) . However, the ability of mAbs to induce receptor internalization showed only partial correlation with anti-tumorigenic activity (Harwerth et al., 1992; Hurwitz et al., 1995) . An obstacle in the understanding of mAb-mediated eects is the possibility that ErbB-2 has a direct ligand, that has not yet been completely characterized (Dougall et al., 1994) . Activation of receptor tyrosine kinases is dependent on receptor dimerization induced by the binding of speci®c ligands (Yarden and Schlessinger, 1987) . However, ErbB-2 may participate in signal transduction even in the absence of a direct ligand, because it forms heterodimeric complexes with its family members, namely ErbB-1 (EGF receptor) and the two NDF/neuregulin receptors, ErbB-3 and ErbB-4 (Goldman et al., 1990; Pinkas-Kramarski et al., 1996; Riese et al., 1995; Wada et al., 1990) . Hierarchical recognition of the dimerization partner oers ErbB-2 a key role in the determination and mediation of signaling and resultant cellular fate . The importance of ErbB-2 as a transregulator expands in light of reported coexpression of ErbB family receptors in malignant cells (Gullick, 1990; Lemoine et al., 1992) , as well as by its ability to reconstitute the aberrant tyrosine kinase activity characteristic of ErbB-3 (Pinkas-Kramarski et al., 1996; Riese et al., 1995; Sliwkowski et al., 1994) . Heterodimer formation between ErbB-2 and ErbB-1 is responsible for synergistic growth signals in cells that co-overexpress the two receptors (Kokai et al., 1989) . A similar synergy was observed upon co-overexpression of ErbB-2 and ErbB-3 (Alimandi et al., 1995; Wallasch et al., 1995) , probably due to the extremely high mitogenic potential of the corresponding receptor heterodimer (Pinkas-Kramarski et al., 1996) . Selective suppression of ErbB-2 expression at the cell surface by means of retention in the endoplasmic reticulum (Beerli et al., 1994) , demonstrated that this molecule can act as a shared signaling subunit of both EGF-and NDFreceptors (Graus-Porta et al., 1995; Karunagaran et al., 1996) that augments and prolongs signaling by deceleration of the rate of ligand dissociation .
The ability of ErbB-2 to serve as a pan ErbB auxiliary receptor subunit implies a versatility of mechanisms by which the receptor is involved in transformation. Hence, attempts to inhibit malignancies should consider the transacting potential of ErbB-2, in addition to its presumed ability to act through homodimer formation. Our study has addressed the possibility that mAbs directed against ErbB-2 might exert at least part of their tumorinhibitory eects via interference with receptorreceptor interactions. A battery of antibodies directed against the extracellular domain of ErbB-2 has been generated and classi®ed into groups according to speci®c epitope recognition. Several classes of tumorinhibitory mAbs that accelerate cellular degradation of ErbB-2 were identi®ed. Interestingly, one class of tumor-inhibitory antibodies partially reduced cellular binding of both NDF and EGF. Consistent with an ability to interfere with receptor crosstalk, these mAbs also reduced the trans-stimulatory eect of ErbB-2 on growth signals. We suggest that anti-ErbB-2 antibodies can inhibit cancer not only by impeding the homodimer-dependent activity, but also by blocking heterodimer formation and receptor crosstalk. This implies wider than currently accounted-for mechanisms that can be utilized for the designing of therapeutically ecient anti-ErbB-2 inhibitors. In addition, our results may be relevant to the mechanism by which EGF-like ligands recruit ErbB-2 into receptor heterodimers.
Results

Classi®cation of anti-ErbB-2 monoclonal antibodies
To study the mechanistic basis of tumor inhibition by certain mAbs to ErbB-2, we extended our antibody repertoire by employing an exhaustive immunization protocol. Essentially, mice were immunized with a recombinant extracellular domain of the human protein and the resulting hybridomas were screened for antibody binding to a cell surface-expressed ErbB-2. A dozen of new mAbs was generated, and analysed together with a panel of ®ve mAbs that we previously described (Stancovski et al., 1991) . The new mAbs were assayed for their ability to aect the tumorigenic growth in nude mice of the N87 human gastric carcinoma cell line overexpressing the ErbB-2 protein. Nine dierent mAbs, or saline as control, were injected intraperitoneally into groups of six mice, on days 3, 7 and 10 after tumor inoculation. Figure 1 depicts tumor progression in the presence of four representative mAbs. The tumorigenic growth of N87 cells was inhibited by 85%, 61% and 82% in nude mice injected with mAbs L26, L140 and L431, respectively. These values correspond to mean of inhibition measured at ®ve time points throughout a period of 46 days post inoculation. Antibody L87 showed no eect on the growth of tumors in vivo, presumably due to its relatively low anity (data not shown). Because previous studies suggested that dierent regions on the extracellular domain of ErbB-2 mediate mAb-dependent eects on tumor growth we examined the dependency of tumor inhibition on speci®c immunogenic determinants by performing a reciprocal binding assay (Figure 2 ). Several mAbs were radiolabeled and their binding to N87 cells was determined in the presence of all other antibodies to enable classi®cation of the mAbs. Thus, antibody L431 was eciently displaced by the strong tumor-inhibitory mAb N12 (Stancovski et al., 1991) , but not by any other antibody (Figure 2A ). Therefore, these mAbs were classi®ed into the same group, denoted Class I. In a similar manner we could categorize mAbs L26, L96, and L288 into a second group, denoted Class II ( Figure 2B ) and mAb L140 into Class III, that comprises only a single antibody. Antibody L87 could be displaced by antibodies from several groups, although it could not fully displace its own binding Figure 1 Inhibition of tumor growth by representative mAbs to ErbB-2. Athymic mice received a subcutaneous injection of 3610 6 N87 human gastric cancer cells that overexpress ErbB-2. Three, 7 and 10 days later monoclonal antibodies (a total dose of 1 mg per animal) were injected intraperitoneally, and tumor volumes were measured at the end of the indicated time periods. Phosphate-buered saline-(PBS-) injected mice were used for control (closed circles). The following mAbs were used: L26 (circles), L87 (rhombuses), L140 (triangles) and L431 (squares). Bars represent standard deviations for groups of ®ve mice. The experiment was repeated three times with each of the mAbs and yielded similar results ( Figure 2D ). This characteristic of mAb L87 is in accordance with its weak precipitating ability of the native ErbB-2 protein and is reinforced by the ability of mAb L87 to recognize the denatured protein (data not shown). The low anity of mAb L87 to conformationally-intact ErbB-2 could underlie the observed pattern of displacement by a wide variety of mAbs. Several additional mAbs (e.g., L151, L242, L219, N28 and N29) were found to react with distinct antigenic determinants of ErbB-2, indicating multiplicity of antigenic sites, of which site II is apparently the most ecient. Anti-ErbB-2 antibody classi®cation is summarized in Table 1 .
Tumor inhibition correlates with mAb-induced receptor internalization but not with kinase activation Upon binding of certain mAbs, ErbB-2 has been shown to undergo internalization (Drebin et al., 1985) in a pathway shared by other growth factor receptors, when induced by ligands and antibodies (Sorkin and Waters, 1993) . Several lines of evidence indicate a correlation between tumor-inhibitory activity of mAbs and their ability to accelerate ErbB-2 uptake and down-regulation (Hurwitz et al., 1995; Tagliabue et al., 1991) . To test the applicability of such a correlation to the new inhibitory mAbs, we studied I-mAb was used as a measure for the degree of antigenic overlap. The following radiolabeled mAbs were used: L431 (A), L288 (B), L140 (C) and L87 (D). The labeled mAbs were added to the medium of N87 cells growing in 96-well culture dishes, in the presence of the same unlabeled antibody (closed circles). Alternatively, unlabeled mAbs representing the dierent classes were used: Class I (squares, N12 in A and C, L431 in B and D), II (circles, L26), III (triangles, L140) and IV (rhombuses, L87 in C). Following 1 h of incubation at 228C, the monolayers of cells were washed three times with PBS and solubilized in an alkaline solution. The results are presented as the mean+s.d. of duplicates. The experiments were repeated thrice their eect on the internalization of membrane-bound ErbB-2. The internalization assay used has not been previously applied to ErbB-2, and it included biotinylation of the surface-exposed protein, followed by exposure to the various mAbs. Molecules that underwent internalization escaped a subsequent digestion with pronase, that was applied extracellularily and were thus visualized by streptavidin detection. A 20 min-long incubation in the presence of mAbs from Class I (represented by L431) revealed a band of approximately 85 kDa, that represents a relatively late degradation product of ErbB-2 (Figure 3) . A similar result was obtained upon incubation with the tumorinhibitory mAb L242 (comprising a single-mAb group), whereas antibodies from Class II caused the appearance of the apparently early proteolytic product of 120 kDa, implying a slower degradation pathway. Internalization of ErbB-2 by mAb L140 (Class III), a moderate inhibitory mAb, resulted in both proteolytic products and a residual intact receptor (185 kDa protein band). Antibody L87 (Class VI), a noninhibitory antibody, induced no detectable internalization of ErbB-2, an eect that was shared with the control IID2 antibody against a-fetoprotein. Because the size of the protein recovered by the internalization assay presumably re¯ects the rate of internalization, the results presented in Figure 3 suggest a dependency of tumor inhibition on the ability of the mAbs to internalize the receptor (Table 1) . Of note, however, is the relatively slow endocytic processing that was induced by Class II mAbs (L26 and L288), implying that their strong anti-tumor eect depends on additional activities.
It has been previously reported that tumorinhibitory eects of anti-ErbB-2 mAbs only partially correlate with modulations of the phosphotyrosine content of the receptor (Kumar et al., 1991; Stancovski et al., 1992) . To examine the relationship between tumor inhibition and stimulation of ErbB-2 phosphorylation, we selected a model cellular system of 32D myeloid cells that ectopically express ErbB-2 in the absence of other ErbB proteins, thereby excluding transphosphorylation eects that widely occur within the ErbB family (Pinkas-Kramarski et al., 1996) . Lysates of antibody-treated cells, immunoblotted for the detection of proteins phosphorylated on tyrosine residues, demonstrated the dependency of ErbB-2 phosphorylation on mAb bivalency (Figure 4 , upper panel). Tumor-inhibitory mAbs from both Class I and Class II (L431 and L26, respectively) caused a comparable extent of phosphorylation, that was absent when the monovalent antibody fragments (Fab) were used. Antibody L140, a moderate cancer eector, exerted maximal elevation of receptor phosphorylation, that was higher than the eect of the tumor-stimulatory mAb, N28 (Stancovski et al., 1991) . This suggests that the ability of antibodies to aect the extent of ErbB-2 phosphorylation re¯ects only their capacity to form ErbB-2 homodimers and as implied by Table 1 it may be independent of the longterm biological activity in vivo. Consistent with its low binding anity, mAb L87 could not mediate a phosphorylation signal upon the receptor.
Class II mAbs inhibit ErbB-2 interactions with ErbB-familiy counterparts
The engagement of ErbB-2 in hetero-complexes with other ErbB-family tyrosine kinases, has been shown to augment both binding and signaling of EGF and NDF when associated with their respective receptors (GrausPorta et al., 1995; Karunagaran et al., 1996; Kokai et al., 1989; Sliwkowski et al., 1994) . To examine whether anti-ErbB-2 mAbs can interfere with heterodimer formation, we used ligand anity as an indicator of ErbB-2 involvement in ligand binding complexes. This
199 -120 -87 - Figure 3 Eect of mAbs on degradation of ErbB-2. Cell surface proteins of con¯uent monolayers of N87 cells (10 cm dishes) were labeled with biotin as described under Materials and methods. The cells were then exposed for 30 min at 48C to the indicated mAbs (at 40 mg/ml). The monolayers were thereafter incubated for 20 min at 378C in order to allow receptor internalization and degradation. At the end of this incubation, the monolayers were transferred back to 48C, treated for 30 min with pronase to digest surface-exposed proteins and cell lysates were prepared. ErbB-2 proteins that escaped hydrolysis by pronase were visualized by immunoprecipitation with the NCT antibody, that was followed by gel electrophoresis, transfer to nitrocellulose ®lter and detection with horseradish peroxidase-labeled streptavidin. Note that only internalized receptor is visualized. For control we incubated the cells in the absence of mAb (lane labeled -) or in the presence of an irrelevant mAb (antibody IID2). The locations of marker proteins are indicated in kilodaltons (kDa). The experiment was repeated twice
190 - Figure 4 Antibody-induced stimulation of ErbB-2 phosphorylation on tyrosine residues. ErbB-2-expressing 32D cells (denoted D2 cells) were incubated for 15 min at 378C with the indicated mAbs at 20 mg/ml, or with their respective monovalent fragments (Fab, 20 mg/ml). Whole cell lysates were then prepared and subjected to gel electrophoresis. The gel-resolved proteins were transferred to a nitrocellulose ®lter that was blotted with an antibody to phosphotyrosine and detected with a secondary antibody. Incubation in the absence of antibody (lane labeled ±) or with an isotope matched control mAb (antibody 6B11) were used for control. The location of a marker protein is indicated in kDa assay was performed on several cell lines, including N87 that expresses ErbB-1, ErbB-2 and ErbB-3 receptors and the human T47D breast cancer cell line, that expresses all four ErbB proteins. Figure 5A depicts the results of binding analyses of radiolabeled NDF and EGF, in the presence of representative mAbs directed against dierent ErbB-2 epitopes. It is important to note that none of the antibodies crossreacted with other ErbB family members. Antibody L26, as well as other Class II mAbs, were able to displace up to 74% and 42% of cell-bound EGF and NDF, respectively. This phenomenon was not characteristic of mAbs capable of recognizing other receptor determinants (e.g., mAbs L431, L87 and L140, Figure 5A ), suggesting that the epitope bound by mAbs from Class II is involved in the formation of heterodimers. This hypothesis was further supported by the inhibition of EGF and NDF binding to T47D cells by monovalent fragments of antibody L26 ( Figure 5B ). Fab fragments of L26 could inhibit the binding of both ligands, to an extent similar to that of the whole mAb, whereas the Fab of an antibody incapable of ligand binding inhibition (N28) could not. It is worth noting that all our ligand binding analyses were performed at 48C, in order to exclude dierences due to ErbB-2 internalization. Similar results were obtained with the N87 cell line (data not shown). To directly test the prediction that Class II mAbs inhibit ligand binding by interfering with the formation of ErbB-2-containing heterodimers, we covalently labeled each receptor with a radiolabeled ligand, and analysed coprecipitation of the anity labeled receptor with ErbB-2. The results of this experiment, that was performed with N87 cells, are shown in Figure 6 . Evidently, both monomeric and dimeric receptor species were precipitated by antiErbB-2 antibodies. However, the presence of mAb L26 during the anity labeling reaction signi®cantly reduced coprecipitation with ErbB-2. The eect was larger with EGF than with NDF, consistent with the results of the ligand displacement assay ( Figure 5A ), and it was not induced by a control non-relevant antibody (6B11). However, all mAbs to ErbB-2 slightly reduced the eciency of anity labeling, especially with EGF, probably due to aspeci®c masking of primary amino groups. To further study the mechanism underlying antibody-induced inhibition of ligand binding we measured the eect of mAb L26 on the anity of EGF and NDF to their receptors ( Figure 7A ). Scatchard analyses revealed a minimal eect on the number of binding sites, but a signi®cant reduction in ligand anities upon co-incubation with a Class II mAb: threefold for EGF and twofold for NDF. Because ErbB-2-containing heterodimers are characterized by a relatively slow rate of ligand association , we tested the prediction that an acceleration in ligand dissociation was responsible for the observed inhibitory eect of mAb L26. The kinetics of EGF and NDF release were determined in the presence or absence of the L26 mAb. Evidently, the mAb signi®cantly increased the rates of dissociation of both ligands from their cellular binding sites ( Figure 7B ). Taken together, the results of ligand binding analyses imply that mAbs belonging to Class II are capable of interfering with the stability of dimers formed between ErbB-2 and its family members, namely EGF-and NDF-receptors.
-
Class II mAbs inhibit transactivation of growthregulatory signals by ErbB-2
Prolonged binding of NDF and EGF achieved by the presence of ErbB-2 is thought to augment growthregulatory signals. Indeed, ErbB-2 has the ability to potentiate the proliferative eect of EGF and to I-EGF in the presence (open circles) or absence (closed circles) of mAb L26 (50 mg/ml). Unbound ligand removal was followed by cell lysis and radioactivity monitoring. Non-speci®c ligand binding was determined in the presence of a 100-fold excess of the unlabeled ligand, and was subtracted from the total amount of ligand that bound at each concentration. The results are presented as Scatchard plots and as saturation curves (insets). Each data point represents an average of a duplicate, and the whole experiment was repeated thrice. (B) Acceleration of ligand dissociation. T47D cells were ®rst incubated for 2 h at 48C with radiolabeled EGF or NDF (each at 20 ng/ml) as indicated. Thereafter, the ligands were removed and the cells incubated with an unlabeled ligand (200 ng/ml) and in the presence (open circles) or absence (closed circles) of mAb L26 (20 mg/ml). Cell-bound as well as released radioactivity were then followed as a function of time of incubation at 48C. The results are expressed as the ratio between the amount of ligand that was bound at time t (B t ) and the initially bound ligand (B 0 ) and they represent the average and standard deviation of duplicates. The experiments were repeated twice
125 I-LIGAND: NDF EGF -180 -180 Figure 6 The eect of mAbs on anity labeling and coimmunoprecipitation of NDF-and EGF-receptors with ErbB-2. Monolayers of con¯uent N87 cells were incubated for 2.5 h with 10 ng/ml of 125 I-labeled NDF-b1 177 ± 246 or EGF, in the presence of mAb L26 (5 and 25 mg/ml, left and right panels respectively), L151 (5 mg/ml), or L431 (25 mg/ml), as indicated. A control mAb, 6B11, was also added (5 and 25 mg/ml, left and right panels respectively). The cell monolayers were washed with PBS and then subjected to anity labeling for 25 min with BS 3 (1 mM), followed by cell lysis. After clearance of cell debris, the detergentsolubilized lysates were subjected to separate immunoprecipitation reactions with NCT, a rabbit polyclonal antiserum directed to the C-terminus of the ErbB-2 protein. Immunocomplexes were resolved by gel electrophoresis on a 6.5% acrylamide gel followed by autoradiography. Note that monomeric receptor is coprecipitated representing ligand bound receptor that is probably involved in heterodimers reconstitute mitogenic signals transmitted by NDF activation of ErbB-3 (Pinkas- Kramarski et al., 1996) . To examine the eect of heterodimer destabilization by antibody L26 on signal transmission by growth factors, we measured the synthesis of DNA in cells expressing the appropriate receptor combinations. 32D cells expressing a combination of ErbB-2 with either ErbB-1 (denoted D12 cells) or with ErbB-3 (D23 cells) showed a decreased potency of the mitogenic eects exerted by EGF and NDF, respectively, when examined in the presence of mAb L26. Consistent with the lower ligand anity exhibited in the presence of antibody L26, the dose-response curves of EGF-and NDF-induced DNA synthesis shifted to higher ligand concentrations. Furthermore, the maximal signal attained declined in the presence of mAb L26 ( Figure  8 ). It is of relevance to note that signals transmitted by EGF were adjusted by the mAb to a greater extent than those of NDF, re¯ecting the dierences exhibited in antibody displacement of each ligand ( Figure 5A ). In conclusion, our results suggest that the tumorinhibitory Class II mAbs can interfere with the ability of ErbB-2 to form the superior heteromeric signaling complexes with NDF-and EGF-receptors.
Discussion
Understanding the molecular mechanisms underlying antibody-induced retardation of tumor growth is essential not only for optimal selection of mAbs for therapy, but it may also help explain the relatively high transforming potential of ErbB-2 in comparison with other receptor tyrosine kinases. In the present study we used a large collection of mAbs to ErbB-2, in an attempt to correlate speci®c intrinsic activities of various mAbs with their tumor-inhibitory potential. This analysis, summarized in Table 1 , led us to the following conclusions: (i) The extracellular domain of ErbB-2 contains multiple (47) non-overlapping antigenic sites that are capable of tumor inhibition. (ii) The intrinsic abilities of mAbs to induce endocytic degradation (Figure 3) , to elevate tyrosine phosphorylation of ErbB-2 (Figure 4) , and to increase DNA synthesis in factor-dependent cells (Pinkas-Kramarski et al., 1996 and data not shown) are independent of a speci®c antigenic determinant. However, all three eects are strictly dependent on antibody bivalency (Hurwitz et al., 1995 and data not shown), implying their association with ErbB-2 homodimers. (iii) All mAbs that are directed to the most antigenic site of ErbB-2 (Class II mAbs) are able to inhibit crosstalk with EGF-and NDF-receptors. Unlike other intrinsic mAb actions, this eect is independent of antibody bivalency, suggesting an association with ErbB-2-containing heterodimers.
It is clear from our results with antibodies L140 (Figures 1 and 4) and N28 (Stancovski et al., 1991) that stimulation of ErbB-2 phosphorylation is not coupled to the eects on tumor growth. This conclusion is consistent with previous reports, including the partial agonist activity of the tumor-inhibitory mAb 4D5 (Kumar et al., 1991) . On the other hand, our experiments with the new set of mAbs to ErbB-2 provide further support for the possibility that tumor inhibition is correlated with ecient antibody-induced endocytic degradation of ErbB-2. Consistent with the observed variation in the extent of ErbB-2 degradation (Figure 3) , the less ecient mAbs L87 and L140, respectively exhibited no or weak tumor-inhibitory eects, and the monovalent fragments of the strong tumor-inhibitory mAbs lost both internalizing and growth-inhibitory activities (data not shown). A linkage between tumor retardation and ErbB-2 endocytosis is also supported by results obtained with an oncogenic rodent mutant of Neu/ErbB-2 (Drebin et al., 1985 (Drebin et al., , 1986 , as well as by biochemical and structural observations with the human ErbB-2 (Hurwitz et al., 1995) . Also supportive is the observation that an antibody combination that accelerates ErbB-2 downregulation, more eciently inhibits tumor growth than each mAb alone (Kasprzyk et al., 1992) .
The relationship between tumor inhibition and the capacity of mAbs to induce trans-inhibition of NDF and EGF is less clear. Thus, although Class II mAbs eciently inhibited tumor growth in vivo, a monovalent antibody fragment completely lost activity as a tumor antagonist (data not shown), but retained its ability to inhibit growth factor binding. Possibly, a monovalent fragment has dierent pharmacokinetic properties in long-term in vivo assays compared to the whole mAb. Nevertheless, the possibility that the tumor-inhibitory potential of Class II mAbs is augmented by their ability to block crosstalk between ErbB-2 and its family members is indirectly supported by several lines of evidence, including the synergistic transforming potential of the combination of ErbB-2 with either ErbB-1 (Kokai et al., 1989) or ErbB-3 (Alimandi et al., 1995; Wallasch et al., 1995) , and the emerging role of ErbB-2 as a signaling subunit of NDF-and EGFreceptors . It is important to note that an antibody to ErbB-2 almost completely blocked the mitogenic eect of NDF on human Schwann cells (Morrisey et al., 1995) , demonstrating the essential role of this co-receptor in NDF-driven normal cell proliferation. Conceivably, overexpression of ErbB-2 can cause transformation through enforcement of either homodimer formation or heterodimers with NDF-and EGF-receptors. According to this model, that is schematically presented in Figure 9 , both types of dimers are potent stimulators of cell transformation, probably because they utilize the very potent coupling of ErbB-2 to the Ras-MAP kinase pathway (Ben-Levy et al., 1994) . It follows that inhibition of either type of receptor dimers may impede tumor growth. However, whilst most tumorinhibitory mAbs act through accelerated clearance of ErbB-2 homodimers from the cell surface, only Class II mAbs are able to directly inhibit the heterodimerdriven oncogenic pathway.
Apart from the implications to the oncogenic potential of the ErbB family, the ®nding that antiErbB-2 mAbs can inhibit binding and signaling by heterologous ErbB ligands, is signi®cant to understanding signal transduction and the mechanism of receptor heterodimerization. It is conceivable that Class II antibodies reduce the anity of NDF and EGF to their direct receptors, because they prevent formation of ErbB-2-containing heterodimers. In fact, other classes of tumor-inhibitory mAbs may exert a similar eect by endocytic removal of ErbB-2 that is available for heterodimerization. An important question, however, remains open, namely: by which mechanism a Class II antibody to ErbB-2 inhibits binding to NDF-and EGF-receptors. Simple depletion of ErbB-2 is unlikely because our ligand binding experiments were performed under conditions that do not allow internalization. Steric hindrance of heterodimer formation is possible, but it is important that only one site of ErbB-2 can mediate the inhibitory eect. We therefore favor the possibility that both NDF and EGF directly bind to ErbB-2, albeit with a very low anity, at a site that is recognized by Class II mAbs. According to this model, EGF-like ligands are bivalent, in analogy to the growth hormone molecule (Cunningham et al., 1991) . We propose that the high anity binding site of each ligand binds to the direct receptor, e.g., ErbB-1 in the case of EGF, but a second low anity site exists on each ligand. A dierent version of this model has recently been proposed on the basis of mutagenesis studies and structural data on EGF-like ligands (Gullick, 1994) .
In conclusion, the identi®cation of a group of antiErbB-2 mAbs that can retard tumor growth, and at the same time inhibit binding of two types of growth factors to their respective receptors, may hint that this unique class of antibodies is superior to other mAbs in certain aspects of immunotherapy. In addition, it may explain why certain combinations of mAbs to ErbB-2 are more potent than each antibody alone in regards to tumor inhibition (Drebin et al., 1988) . Finally, if the attribution of bivalency to ErbB ligands is correct, then Class II mAbs may provide a convenient way to map the putative low anity binding site on ErbB-2. Figure 9 Proposed mode of action of tumor-inhibitory antibodies to ErbB-2. ErbB family receptors are shown as membranetransversing bilobular structures, of which ErbB-2 is depicted in gray. For simplicity only one of the NDF receptors, namely ErbB-3 is shown, and its impaired tyrosine kinase activity is illustrated by a cross in the intracellular domain. According to this model, overexpression of ErbB-2 can cause tumorigenicity in one of two ways. First, homodimers of ErbB-2 are spontaneously stabilized, probably as a result of high density expression at the cell surface. Alternatively, ErbB-2-containing heterodimers that are driven by both EGF and NDF cause tumoriginicity due to sensitization to growth factor action. Tumor-inhibitory monoclonal antibodies to ErbB-2 presumably act by blocking either signaling pathway: most inhibitory mAbs accelerate endocytosis of ErbB-2, probably by stabilizing receptor homodimerization. Class II mAbs, such as L26, are characterized by their exclusive ability to block heterodimer formation by ErbB-2, and thereby their action may be superior to other types of antibodies to ErbB-2
Materials and methods
Materials, cell lines and antibodies
Anity-puri®ed rabbit anti-mouse F(ab') 2 was from Jackson Immunoresearch (West Grove, PA). It was radiolabeled with Na 125 I (Amersham) by using the chloramine T method. Sepharose-protein A was purchased from Bio-Rad. The NCT antiserum was raised against a synthetic peptide comprising the 15 C-terminal amino acids of the human ErbB-2. Monoclonal anti-phosphotyrosine antibody (PY-20) was purchased from Santa-Cruz Biotechnology (Santa-Cruz, CA). EGF (human, recombinant) was purchased from Boehringer Mannheim. A recombinant form of NDF-b1 177 ± 264 was obtained from Amgen (Thousand Oaks, CA). mAbs 6B11-D2 against hepatitis B and IID2 against a-fetoprotein were used as controls. Binding buer contained Dulbecco modi®ed Eagle's medium (DMEM) with 5% bovine serum albumin. The N87 human gastric cancer cell line (Trepel et al., 1990) was obtained from Rick King. The HER2 and HER2X cell lines, two derivatives of NIH3T3 cells overexpressing HER2/ErbB-2 (Hudziak et al., 1987) or the secreted extracellular domain were generously given by Axel Ullrich. T47D human breast cancer cells were from the American Type Culture Collection (Rockville, MD). 32D myeloid cells that ectopically express ErbB-2 (D2 cells), or combinations of ErbB-2 with either ErbB-1 (D12 cells) or with ErbB-3 (D23 cells) were previously described (PinkasKramarski et al., 1996) .
Experimental animals
BALB/c mice, CB6/F 1 mice and CD1/nude mice were obtained from the Experimental Animals Center of the Weizmann Institute of Science.
Generation of monoclonal antibodies to ErbB-2
The puri®ed extracellular domain of ErbB-2 secreted from HER2X cells was used to immunize BALB/C mice. 10 mg of the antigen were injected twice into the foot pads, followed by three intraperitoneal injections at intervals of 2 weeks. Antisera were tested by immunoprecipitation using HER2 cells labeled metabolically with [
35 S]methionine. Splenocytes from a selected mouse were fused with NSO myeloma cells and hybridomas selected with hypoxanthine/ aminopterin/thymidine medium. Supernatants of the cells were screened by using the following indirect binding assay: N87 cells overexpressing the ErbB-2 protein were plated on a¯exible 96-well plate pre-coated with ®bronectin (10 mg/ml) and allowed to attach overnight at 378C. Supernatants of the hybridomas were added to the cells for 1 h at 228C and bound antibodies were detected with 125 I-labeled rabbit anti-mouse F(ab') 2 antibody. Positive hybridomas were cloned by limiting dilution and antibody class determined with class-speci®c second antibodies. Large quantities of mAbs were produced by preparation of ascites¯uid in BALB/C mice. The antibodies were puri®ed by using the caprylic acid method (Russ et al., 1983) .
Determination of mAb eect on tumor growth in vivo N87 cells (5610 6 ) were injected subcutaneously into nude mice, followed by three intraperitoneal injections of the mAbs on days 3, 7 and 10. Groups of six mice received a total dose of 1 mg/mouse. Tumor parameters were measured once a week with calipers, and tumor volume was calculated according to the formula: Tumor volume=length6width6height.
Competitive binding assay of mAbs to ErbB-2 N87 cells were grown to con¯uence in 96-well plates. Selected antibodies (e.g., L431, L288, L140, and L87) were labeled with Na 125 I by using the chloramine-T method. The radiolabeled antibody (10 5 c.p.m./well) was added to the cells together with increasing concentrations of each mAb in its unlabeled form, for 1 h at 228C. After washing with PBS, the cells were solubilized in 0.1 N NaOh solution containint 0.1% SDS, and radioactivity was determined by g-counter.
Cell lysate preparation and immunoprecipitation
Cells grown as monolayers were solubilized by the addition of lysis buer containing 50 mM HEPES, pH 7.5, 150 mM NaCl, 10% glycerol, 1% Triton X-100, 1 mM EDTA, 1 mM EGTA, 1 mM MgCl 2 , 1 mM phenlymethylsulfonyl¯uoride, 0.5 mM Na 3 VO 4 , 5 mg/ml leupeptin and 5 mg/ml aprotonin. Following 30 min of incubation at 48C, cell debris and nuclei were cleared by centrifugation. For direct electrophoretic analysis, boiling gel sample buer was added. For other analyses, samples were ®rst subjected to immunoprecipitation.
Determination of tyrosine phosphorylation
32D cells expressing ErbB-2 (D2 cells) were incubated in 1 ml PBS containing various mAbs (each at 20 mg/ml) for 15 min at 378C. The antibodies were removed by washing (three times) with ice-cold PBS and subjected to solubilization. Whole cell lysates were separated by gel electrophoresis, transferred to nitrocellulose and immunoblotted with an anti-phosphotyrosine antibody (PY-20).
Radiolabeling of ligands and ligand binding analyses
Recombinant human EGF and NDF-b1 177 ± 246 were labeled with iodogen (Pierce) as described previously . The speci®c activity ranged between 1 and 5610 5 c.p.m./ng. For ligand displacement analyses, conuent monolayers of cells in 48-well plates were washed once with binding buer. The cells were then co-incubated, for 2 h at 48C, with 10 ng/ml of 125 I-EGF or 125 I-NDFb1 177 ± 246 in the presence of increasing concentrations of mAbs. Following washing with ice-cold binding buer (thrice), cells were lysed in 0.1 N NaOH/0.1% SDS, and radioactivity was determined. For Scatchard analysis, cells were incubated for 2 h at 48C with dierent concentrations of the radiolabeled ligand, in the presence or absence of mAb L26 (50 mg/ml). Non-speci®c binding was determined by the addition of 100-fold excess of the unlabeled ligand together with the corresponding labeled ligand. Scatchard analysis was performed by using the computerized program LIGAND (Munson and Rodbard, 1980) .
Covalent cross-linking analysis
Monolayers of cells (5610 6 /ml) were incubated on ice for 2.5 h with either 125 I-EGF (10 ng/ml) or 125 I-NDF-b1 177 ± 246 (10 ng/ml). The chemical crosslinking reagent BS 3 (Sigma, St. Louis, MO) was then added (1 mM ®nal concentration) and after 25 min at room temperature, cells were washed with PBS, and cell lysates were prepared for immunoprecipitation analysis. The cells were scraped with a rubber policeman into 1 ml of PBS, mixed, and centrifuged (10 000 g, 10 min, 48C). The cell pellet was mixed with 0.8 ml of solubilization buer and centrifuged again. The proteins in the lysate supernatants were immunoprecipitated with aliquots of protein A-Sepharose bound to the NCT antibody for 1 h at 48C. Immunoprecipitates were then washed three times with 1 ml of HNTG solution (20 mM HEPES pH 7.5, 0.15 M NaCl, 0.1% Triton X-100, 10% glycerol).
Detection of endocytosed ErbB-2
Surface proteins of N87 cells in 6-well plates, were biotinylated by incubation for 30 min at 48C with 0.5 mg/ml N-hydroxysuccinimide long chain biotin (NHS-LC-biotin, Pierce, Rockford, IL) in a solution containing NaCl (150 mM) and borate buer (10 mM, pH 8.5) (LevyToledano et al., 1993) . The reaction was quenched by washing the dishes three times with ice-cold PBS containing glycine (15 mM). Cells were incubated in the presence of mAbs (40 mg/ml) for 30 min at 48C and transferred to 378C for 20 min, to allow receptor internalization. Thereafter, cell surface proteins were subjected to pronase digestion by incubating the cells for 30 min at 48C in medium containing pronase (1.46 mg/ml) and HEPES (20 mM, pH 7.6). Pronase activity was blocked by washing the cells three times with ice-cold PBS containing bovine serum albumin (10 mg/ml). Cell lysates were immunoprecipitated by a polyclonal antibody against the intracellular domain of ErbB-2. Immunoprecipitates were washed by high-medium-and low-salt buers (Goldman et al., 1990) , eluted with gel sample buer and resolved by gel electrophoresis. Proteins were transferred to nitrocellulose, probed by horseradish peroxidase-labeled streptavidin, and detected by using a chemiluminescence kit (Amersham).
Analysis of ligand dissociation
Cell monolayers in 48-well plates were incubated with 10 ng/ml 125 I-EGF or 125 I-NDF-b1 177 ± 246 for 2 h at 48C, and then washed with ice-cold binding buer (thrice). Ligand dissociation was measured by incubating the cells in binding buer with the corresponding unlabeled ligand (400 ng/ml) in the presence or absence of mAb L26 (20 mg/ ml) for various periods of time at 48C. Non-speci®c binding and release of radiolabeled ligand were determined in parallel and subtracted from the total amount of bound ligand at each time point. The data were analysed by plotting the natural logarithm of B t /B 0 versus time, B t being the concentration of bound ligand at time t, and B 0 is the same at the starting time of dissociation.
Thymidine incorporation assay
The incorporation of [methyl-3 H]thymidine into DNA in 32D cells expressing ErbB family receptors was measured as previously described (Pinkas-Kramarski et al., 1996) . Cells were washed free of interleukin-3 and resuspended in RPMI-1640 medium at 5610 5 cells/ml. Serial dilutions of either EGF or NDF-b1 177 ± 246 were added to 96-well plates containing 100 ml of cell suspension and 0.1 mCi [methyl-
3 H]thymidine. Cells were incubated for 18 h at 378C in the presence or absence of 50 mg/ml mAb L26. Following cell harvesting, radioactivity incorporated into macromolecules was measured by b-scintillation counting.
